MXPA06012960A - Administracion transdermal de ficotoxinas. - Google Patents
Administracion transdermal de ficotoxinas.Info
- Publication number
- MXPA06012960A MXPA06012960A MXPA06012960A MXPA06012960A MXPA06012960A MX PA06012960 A MXPA06012960 A MX PA06012960A MX PA06012960 A MXPA06012960 A MX PA06012960A MX PA06012960 A MXPA06012960 A MX PA06012960A MX PA06012960 A MXPA06012960 A MX PA06012960A
- Authority
- MX
- Mexico
- Prior art keywords
- propinoperhydropurine
- tricyclic
- effective amount
- pharmaceutical compositions
- transdermal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Se describen composiciones farmaceuticas para interferir con la transmision neuronal que comprenden una cantidad efectiva de por lo menos una 3,4-propinoperhidropurina triciclica; se proporcionan preparaciones para rejuvenecimiento facial que comprenden un cantidad efectiva de la composicion de la invencion y una crema facial; se proporcionan metodos para interferir con la transmision neuronal que comprenden la aplicacion topica de una cantidad efectiva de las composiciones farmaceuticas de la invencion; en otro aspecto de la invencion, se proporcionan cantidades efectivas de las composiciones farmaceuticas y un sistema terapeutico transdermico para la administracion transdermica de por lo menos una 3,4-propinoperhidropurina triciclica; la composicion farmaceutica comprende por lo menos una 3,4-propinoperhidropurina triciclica; y pueden formularse para suministro transdermico del farmaco; el sistema de suministro transdermico del farmaco puede ser un material compuesto laminado que comprende una capa de soporte, un deposito de farmaco y un medio para fijar el material compuesto a la piel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56911204P | 2004-05-07 | 2004-05-07 | |
PCT/US2005/015819 WO2005110418A2 (en) | 2004-05-07 | 2005-05-06 | Transdermal administration of phycotoxins |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06012960A true MXPA06012960A (es) | 2007-06-12 |
Family
ID=35394660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06012960A MXPA06012960A (es) | 2004-05-07 | 2005-05-06 | Administracion transdermal de ficotoxinas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US8377951B2 (es) |
EP (1) | EP1796676B1 (es) |
JP (1) | JP2007538010A (es) |
CN (1) | CN101123967A (es) |
AU (1) | AU2005244096B2 (es) |
BR (1) | BRPI0510760A (es) |
CA (1) | CA2607206C (es) |
ES (1) | ES2568953T3 (es) |
HK (1) | HK1109332A1 (es) |
MX (1) | MXPA06012960A (es) |
WO (1) | WO2005110418A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110417A1 (en) * | 2004-05-07 | 2005-11-24 | Phytotox Limited | Phycotoxins and uses thereof |
US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
US8658699B2 (en) * | 2008-05-19 | 2014-02-25 | Massachusetts Institute Of Technology | Chemical permeation enhancers enhance nerve blockade by toxins |
US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
WO2010117996A1 (en) * | 2009-04-08 | 2010-10-14 | Children's Medical Center Corporation | Prolonged duration local anesthesia with minimal toxicity |
EP2459565B1 (en) | 2009-05-07 | 2018-05-02 | The Board of Trustees of The Leland Stanford Junior University | Saxitoxin derivatives, methods and compositions for studying, imaging, and treating pain |
JP6112867B2 (ja) | 2010-02-10 | 2017-04-12 | ファイトトックス リミテッドPhytotox Limited | サキシトキシン誘導体での触覚の喪失の処置 |
US9750683B2 (en) * | 2012-02-17 | 2017-09-05 | Veloce Biopharma, Llc | Antifungal compositions for the treatment of skin and nails |
EP2638908A1 (en) * | 2012-03-16 | 2013-09-18 | Phytotox SpA | Paralytic Shellfish Poison |
CN104602703A (zh) * | 2012-03-22 | 2015-05-06 | 雷文斯治疗公司 | 使用局部化学性去神经支配剂处理皱纹的方法 |
JP6313420B2 (ja) | 2013-03-15 | 2018-04-18 | ザ チルドレンズ メディカル センター コーポレイション | 持続する局所麻酔のためのネオサキシトキシン併用製剤 |
AU2015243437B2 (en) | 2014-04-09 | 2019-08-29 | Siteone Therapeutics, Inc. | 10',11'-modified saxitoxins useful for the treatment of pain |
ES2895155T3 (es) | 2015-09-30 | 2022-02-17 | Siteone Therapeutics Inc | Saxitoxinas modificadas en 11,13 para el tratamiento del dolor |
WO2018183781A1 (en) | 2017-03-29 | 2018-10-04 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
WO2018183782A1 (en) | 2017-03-29 | 2018-10-04 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
US11338308B2 (en) | 2018-08-09 | 2022-05-24 | Kao Corporation | Method for producing wearable coating |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957966A (en) * | 1972-05-19 | 1976-05-18 | Gaf Corporation | Stabilized vitamin food coatings |
US4022899A (en) * | 1973-06-12 | 1977-05-10 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
US4001413A (en) * | 1973-06-12 | 1977-01-04 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic composition employing saxitoxin |
US4029794A (en) * | 1973-06-12 | 1977-06-14 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic composition |
US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4906463A (en) | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
US4915950A (en) | 1988-02-12 | 1990-04-10 | Cygnus Research Corporation | Printed transdermal drug delivery device |
US5091186A (en) | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
US5183462A (en) * | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5246705A (en) | 1992-04-08 | 1993-09-21 | Cygnus Therapeutic System | Occlusive, elastomeric backing materials in transdermal drug delivery systems, and associated methods of manufacture and use |
US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
DK1086702T3 (da) * | 1994-05-09 | 2005-05-23 | William J Binder | Præsynaptiske neurotoksiner til behandling af migrænehovedpine |
US5504117A (en) * | 1994-05-27 | 1996-04-02 | Neptune Pharmaceutical Corporation | Pharmacologic preparation for the treatment of anal disorders |
JP3517031B2 (ja) * | 1995-06-09 | 2004-04-05 | 日清紡績株式会社 | 生物学的活性物質の分析法 |
US5837265A (en) * | 1996-03-08 | 1998-11-17 | The Regents Of The University Of California | Chemically-modified clostridiatoxin with improved properties |
US5721215A (en) * | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
WO1998009523A1 (en) * | 1996-09-05 | 1998-03-12 | Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
CN1081034C (zh) | 1997-03-07 | 2002-03-20 | 潘心富 | 一种双胍基氢化嘌呤环类化合物的戒毒药 |
WO1998043619A2 (en) | 1997-04-02 | 1998-10-08 | The Regents Of The University Of California | Method of local anesthesia |
WO1998051290A2 (en) | 1997-05-16 | 1998-11-19 | Children's Medical Center Corporation | Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent |
DE69833942T3 (de) * | 1997-07-15 | 2010-06-10 | The Regents Of The University Of Colorado, Boulder | Verwendung einer neurotoxintherapie zur behandlung von prostataerkrankungen |
US6432986B2 (en) * | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
US6159944A (en) * | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
JP2002528421A (ja) * | 1998-10-27 | 2002-09-03 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 創傷治癒の促進方法 |
US6299902B1 (en) | 1999-05-19 | 2001-10-09 | The University Of Georgia Research Foundation, Inc. | Enhanced transdermal anesthesia of local anesthetic agents |
US6265379B1 (en) * | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
US6337075B1 (en) * | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) * | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
IL137559A (en) * | 2000-07-27 | 2006-12-31 | Amnon Sintov | A system for administering drugs through the skin |
CN1284536C (zh) * | 2000-09-18 | 2006-11-15 | 威克斯医药有限公司 | 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用 |
CN1203857C (zh) * | 2000-09-18 | 2005-06-01 | 威克斯医药有限公司 | 局部麻醉与镇痛的新方法 |
CN1240702C (zh) * | 2000-09-18 | 2006-02-08 | 威克斯医药有限公司 | 高获得率提取替曲朵辛的方法 |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
CN1236773C (zh) * | 2000-11-22 | 2006-01-18 | 南宁枫叶药业有限公司 | 用于镇痛、麻醉或治疗药物依赖性的制剂 |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
CN1382443A (zh) * | 2001-04-25 | 2002-12-04 | 威克斯医疗仪器有限公司 | 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用 |
CN1269482C (zh) * | 2001-05-18 | 2006-08-16 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
KR20100135884A (ko) * | 2001-11-15 | 2010-12-27 | 마이크로 알제 코포레이션 | 3, 4-프로피온퍼하이드로퓨린을 포함하는 약학 조성물 및 상기 조성물을 이용한 신경 전달의 블로킹 방법 |
CN1194693C (zh) | 2002-01-11 | 2005-03-30 | 中国科学院海洋研究所 | 麻痹性贝毒毒素作为制备疗治疼痛病症药物的应用 |
US20030224020A1 (en) | 2002-05-31 | 2003-12-04 | Zabudkin Alexander F. | Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
AU2003298837A1 (en) * | 2002-12-02 | 2004-06-23 | Massachusetts Institute Of Technology | Prolonged suppression of electrical activity in excitable tissues |
WO2005110417A1 (en) * | 2004-05-07 | 2005-11-24 | Phytotox Limited | Phycotoxins and uses thereof |
-
2005
- 2005-05-06 ES ES05746905.8T patent/ES2568953T3/es active Active
- 2005-05-06 JP JP2007511630A patent/JP2007538010A/ja active Pending
- 2005-05-06 MX MXPA06012960A patent/MXPA06012960A/es unknown
- 2005-05-06 CN CNA2005800227688A patent/CN101123967A/zh active Pending
- 2005-05-06 BR BRPI0510760-1A patent/BRPI0510760A/pt not_active IP Right Cessation
- 2005-05-06 AU AU2005244096A patent/AU2005244096B2/en not_active Ceased
- 2005-05-06 WO PCT/US2005/015819 patent/WO2005110418A2/en active Application Filing
- 2005-05-06 CA CA2607206A patent/CA2607206C/en active Active
- 2005-05-06 EP EP05746905.8A patent/EP1796676B1/en active Active
- 2005-05-06 US US11/568,751 patent/US8377951B2/en active Active
-
2007
- 2007-12-20 HK HK07113984.4A patent/HK1109332A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2005244096A1 (en) | 2005-11-24 |
WO2005110418A3 (en) | 2007-06-07 |
WO2005110418A2 (en) | 2005-11-24 |
BRPI0510760A (pt) | 2007-11-20 |
EP1796676A2 (en) | 2007-06-20 |
EP1796676B1 (en) | 2016-03-09 |
EP1796676A4 (en) | 2008-06-25 |
US20080045553A1 (en) | 2008-02-21 |
ES2568953T3 (es) | 2016-05-05 |
JP2007538010A (ja) | 2007-12-27 |
CA2607206C (en) | 2016-06-14 |
CA2607206A1 (en) | 2005-11-24 |
CN101123967A (zh) | 2008-02-13 |
HK1109332A1 (zh) | 2008-06-06 |
US8377951B2 (en) | 2013-02-19 |
AU2005244096B2 (en) | 2011-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA06012960A (es) | Administracion transdermal de ficotoxinas. | |
Sorge et al. | Transdermal buprenorphine in the treatment of chronic pain: resultsof a phase III, multicenter, randomized, double-blind, placebo-controlled study | |
UA88464C2 (ru) | Способ дермального введения метадоновой композиции с обеспечением системного действия | |
MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
AR056453A1 (es) | Composiciones con estrogeno y metodos terapeuticos para su uso | |
TW200612987A (en) | Combination treatment for non-hematologic malignancies | |
WO2004105702A3 (en) | Foamable pharmaceutical compositions and methods for treating a disorder | |
WO2006041908A3 (en) | Transdermal delivery of estradiol | |
BR0316004A (pt) | Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina | |
HK1083009A1 (en) | Topical drug delivery using phosphatidylcholine | |
WO2009002867A3 (en) | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement | |
WO2005051297A3 (en) | Combination drug therapy to treat obesity | |
WO2007092284A3 (en) | Low dose no donor-containing transdermal patch | |
WO2006012213A3 (en) | Composition and method for delivery of phytochemicals | |
WO2011029948A3 (de) | Transdermales therapeutisches system zur verabreichung von fentanyl oder einem analogstoff davon | |
WO2005007072A3 (en) | Methods and pharmaceutical compositions for healing wounds | |
TW200738287A (en) | Nicotine transdermal delivery system | |
MX2009014102A (es) | Sistema de administración transdérmica que comprende glicopirrolato para tratar sialorrea. | |
PL1680128T3 (pl) | Heksafosforan mio-inozytolu do stosowania miejscowego | |
AU2003215657A1 (en) | Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion. | |
WO2008116004A3 (en) | Transdermal patch and method for delivery of vitamin b12 | |
WO2005117871A3 (en) | Pharmaceutical compositions for the treatment of pruritus | |
TNSN07203A1 (en) | Pharmaceutical compositions for the treatment of cellulite | |
WO2007113531A8 (en) | Topical drug delivery | |
WO2005009217A3 (en) | Diagnosis of pre-cancerous conditions using pcdgf agents |